Why GSK's Experimental HIV Drug Could Be a Safer Bet—And a Headache for Gilead – Fortune
Fortune |
Why GSK’s Experimental HIV Drug Could Be a Safer Bet—And a Headache for Gilead
Fortune The two-drug combo could prove less toxic. An experimental therapy from GlaxoSmithKline GSK -0.03% could be just as effective as existing therapies DRUGS?? for HIV/AIDS patients without the corresponding risk of toxic side effects, raising the … GlaxoSmithKline’s New Drug Challenges HIV Treatment Orthodoxy Glaxo’s two-drug HIV bet looks good in phase 3 studies Positive Results From First Phase III Studies of Investigational Two-Drug HIV Treatment Regimen |
View original article
Author:
Powered by WPeMatico
Health Topic Contributor
Editors and curators bringing you the latest and most impactful health news. Truly objective, we print links to stories and studies that may contradict one another. If you're searching for news on health studies, alternative health modalities, facts on modern allopathic medicine, and more, we're you're team bringing you the stories and facts that matter.